Mastite puerperal (1991)
- Authors:
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- Assunto: GINECOLOGIA
- Language: Português
- Imprenta:
- Descrição física: 10p
-
ABNT
HEGG, Roberto e BARROS, A C S D. Mastite puerperal. . São Paulo: Sandoz. . Acesso em: 11 fev. 2026. , 1991 -
APA
Hegg, R., & Barros, A. C. S. D. (1991). Mastite puerperal. São Paulo: Sandoz. -
NLM
Hegg R, Barros ACSD. Mastite puerperal. 1991 ;[citado 2026 fev. 11 ] -
Vancouver
Hegg R, Barros ACSD. Mastite puerperal. 1991 ;[citado 2026 fev. 11 ] - Eficacia, tolerabilidade e aceitabilidade do estradiol transdermico no tratamento dos sintomas da menopausa
- Sindrome do climaterio: conceito, importancia e epidemiologia
- Evaluation the predictive value of biomarkers for efficacy outcomes in response to pertuzumab and trastuzumab based therapy: An exploratory analysis of the tryphaena study
- Câncer da mama: quadro clínico, diagnóstico e estadiamento
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA)
- Galactorreia: sindrome hiperprolactinemica
- Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
- Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial
- Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
